Cardiovascular genetic medicine will need a different patient-finding infrastructure

Genetic medicines are changing who cardiovascular trials need to find. Eligibility is increasingly defined by a genotype or a biomarker level, and the people who meet those criteria sit inside populations of millions. Familial hypercholesterolemia affects roughly 1 in 300 people , and elevated lipoprotein(a) is even more common.